Mutation Clinical Trials in Shanghai, Shanghai Municipality
24 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 24 trials
Recruiting
Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 3
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Phase 3
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Non-Small Cell Lung Cancer With HER2- Mutations
Jiangsu HengRui Medicine Co., Ltd.300 enrolled1 locationNCT06430437
Recruiting
Phase 1
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Solid Tumors Harboring a TP53 Y220C Mutation
Changchun GeneScience Pharmaceutical Co., Ltd.82 enrolled1 locationNCT06908434
Recruiting
Phase 1Phase 2
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Breast CancerOvarian CancerProstate Cancer+3 more
Acerand Therapeutics (Shanghai) Limited298 enrolled14 locationsNCT06380660
Recruiting
Phase 1Phase 2
Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)
Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
VeonGen Therapeutics GmbH15 enrolled1 locationNCT07002398
Recruiting
Phase 1
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.120 enrolled1 locationNCT07142980
Recruiting
Phase 1Phase 2
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989
Recruiting
Phase 2
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University40 enrolled1 locationNCT06970353
Recruiting
Phase 1
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Gliomas Harboring IDH1 and/or IDH2 Mutations
Hutchmed52 enrolled1 locationNCT07025018
Recruiting
Phase 1
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd30 enrolled2 locationsNCT06666270
Recruiting
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal CancerBRAF V600 Mutation
Fudan University100 enrolled1 locationNCT06749015
Recruiting
Phase 2
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
Shanghai Jiatan Pharmatech Co., Ltd20 enrolled1 locationNCT06124963
Recruiting
Phase 2
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd54 enrolled5 locationsNCT06668103
Recruiting
Phase 2
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
BRAF V600E Mutation PositiveAmeloblastoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University12 enrolled1 locationNCT06653517
Recruiting
Phase 2
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Relapse/RecurrenceAML, ChildhoodRefractory AML+2 more
Children's Hospital of Soochow University50 enrolled12 locationsNCT06316960
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
Non-Small Cell Lung Cancer With EGFR Mutation
Suzhou Genhouse Bio Co., Ltd.94 enrolled6 locationsNCT06306456
Recruiting
Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728
Recruiting
Phase 2
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Lung Adenocarcinoma Stage IIILung Adenocarcinoma Stage IVEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China96 enrolled1 locationNCT05503667
Recruiting
Phase 1Phase 2
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd.183 enrolled44 locationsNCT04270591